Mineralys Therapeutics, Inc. (MLYS) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
MLYS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MLYS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export MLYS earnings history in CSV or JSON format
Free sign-in required to download data
Mineralys Therapeutics, Inc. (MLYS) Earnings Overview
As of May 8, 2026, Mineralys Therapeutics, Inc. (MLYS) reported trailing twelve-month net income of -$152M, reflecting +37.4% year-over-year growth. The company earned $-1.83 per diluted share over the past four quarters.
Looking at the long-term picture, MLYS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2020.
Mineralys Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CORT ($48M net income, 13.1% margin), SPRB (-$39M net income), INVA ($504M net income, 63.8% margin), MLYS has comparable earnings metrics. Compare MLYS vs CORT →
MLYS Earnings vs Peers
Earnings metrics vs comparable public companies
MLYS Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$155M | +13.0% | -$171M | $-2.29 | - | - |
| 2024 | -$178M | -147.3% | -$192M | $-3.66 | - | - |
| 2023 | -$72M | -141.3% | -$85M | $-1.99 | - | - |
| 2022 | -$30M | -53.5% | -$31M | $-5.77 | - | - |
| 2021 | -$19M | -466.5% | -$19M | $-3.89 | - | - |
| 2020 | -$3M | - | -$3M | $-0.74 | - | - |
See MLYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMLYS — Frequently Asked Questions
Quick answers to the most common questions about buying MLYS stock.
Is MLYS growing earnings?
MLYS EPS is $-1.83, with earnings growth accelerating to +37.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-152M.
What are MLYS's profit margins?
Mineralys Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MLYS's earnings?
MLYS earnings data spans 2020-2025. The accelerating earnings trend is +37.4% YoY. Historical data enables comparison across business cycles.